Medall is a diagnostics and healthcare services startup based in Chennai, India, that provides diagnostic services for patients.

This Startup Deep Dive explains what Medall does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Medall in Brief

• What it is: Medall is an Indian Diagnostics chain company based in Chennai.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• Medall is an integrated pathology and radiology diagnostics company.
• It offers over 1,300 lab tests, 800+ radiology studies, preventive health check packages and home sample collection.
• It cites 7,500+ collection touchpoints across South India and over 200 in-house pathologists and radiologists (company-stated).
• Funding: Peepul Capital reportedly invested about Rs 300 crore in total (reported).

Medall Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Medall?

Medall operates in the Diagnostics chain space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Medall.

• Medall is an integrated pathology and radiology diagnostics company.
• It offers over 1,300 lab tests, 800+ radiology studies, preventive health check packages and home sample collection.
• It cites 7,500+ collection touchpoints across South India and over 200 in-house pathologists and radiologists (company-stated).
• Cities served include Chennai, Tirunelveli, Bangalore, Mysore and Visakhapatnam.

The Origin Story of Medall

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Raju Venkatraman.
• Medall was formerly Precision Diagnostics, a Chennai pathology chain.
• In 2009 Peepul Capital partnered with entrepreneur Raju Venkatraman to acquire the business and rebrand it Medall (reported).
• Raju Venkatraman is described as founder, chairman and CEO; one article spells the name differently.

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Diagnostics chain sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2009: Peepul Capital and Raju Venkatraman acquired Precision Diagnostics (reported initial Peepul investment $20 million for about 18% in one report).
• 2011-2013: industry awards including a Frost and Sullivan award for emerging diagnostics provider.
• 2015: Manipal talks at about Rs 1,000 crore fell through over valuation.
• 2018: Constellation Alpha Capital agreed to buy it at Rs 1,450 crore enterprise value; the deal later fell through.

Medall Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• 2009: Peepul Capital (about $20 million initially, reported).
• Peepul reportedly put in about Rs 300 crore in total and owned about 80% at the time of one report.
• Sale attempts: Abraaj (advanced talks, around 2015-16), global PE funds in 2016, Constellation Alpha (2018), Fosun (reported).

How Does Medall Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Revenue comes from diagnostic tests (pathology and radiology) sold through own centres, collection points and home collection.
• Growth has been by acquisitions: 24 completed acquisitions as of 2018.

The Numbers: Medall Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• As of 2018: over 25 million tests for over 9 million customers in the latest fiscal year.
• Revenue grew about 17% a year (FY13-FY18); adjusted EBITDA about 27% a year; adjusted EBITDA margin rose from 19% to 28%.
• No absolute revenue figure found.

Market Opportunity for Medall

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• India's diagnostics market is fragmented; Medall was described as a top-five diagnostics company by revenue in 2018 and a dominant South India player.
• Network counts differ by date (60+ labs in 2015, nearly 185 labs in later reports).

Technology and Product at Medall

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Home sample collection and NABL-accredited reference laboratories.

Team and Culture at Medall

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Raju Venkatraman, founder, chairman and CEO.
• Peepul Capital (co-founder Sandeep Reddy) was the main investor.

Medall Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Medall

• Latest financial figures found date from 2018.
• Fragmented market with strong national chains and online players.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Medall Growth Outlook: What to Watch

• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Medall can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Medall Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Medall

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Medall.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Medall

Studying a company in the Diagnostics chain space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Medall.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Medall as a Startup

• Customer clarity: Can Medall name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Medall is part of India’s growing Diagnostics chain ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Medall FAQs: Frequently Asked Questions

What is Medall?

Medall is a diagnostics and healthcare services startup based in Chennai, India, that provides diagnostic services for patients. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Medall?

Medall was founded by Raju Venkatraman, and the company reports a founding year of 2009 (Precision Diagnostics acquired and rebranded Medall).

How much funding has Medall raised?

Peepul Capital reportedly invested about Rs 300 crore in total (reported). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Medall make money?

Medall earns revenue from its Diagnostics chain products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Medall?

Reported rivals include Dr Lal PathLabs, Metropolis Healthcare, Vijaya Diagnostic, Neuberg Diagnostics. See the competitor comparison above for how they differ.

What are the main risks for Medall?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Deciml — Deciml: round-up investing app that raised $3M seed | Fyers — Fyers: Bengaluru discount broker founded by the Khoday brothers. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.